1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > GlycoMimetics, Inc. - Product Pipeline Review - 2015

GlycoMimetics, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 31 pages

GlycoMimetics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘GlycoMimetics, Inc. - Product Pipeline Review - 2015’, provides an overview of the GlycoMimetics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GlycoMimetics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GlycoMimetics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GlycoMimetics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GlycoMimetics, Inc.’s pipeline products

Reasons to buy

- Evaluate GlycoMimetics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GlycoMimetics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GlycoMimetics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GlycoMimetics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlycoMimetics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of GlycoMimetics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

GlycoMimetics, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
GlycoMimetics, Inc. Snapshot 5
GlycoMimetics, Inc. Overview 5
Key Information 5
Key Facts 5
GlycoMimetics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
GlycoMimetics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
GlycoMimetics, Inc. - Pipeline Products Glance 12
GlycoMimetics, Inc. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
GlycoMimetics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
GlycoMimetics, Inc. - Drug Profiles 14
GMI-1271 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
GMI-1051 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
GMI-1051 Follow-Ons 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
GMI-1359 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Small Molecule to Inhibit Galectin-1, 3, 9 for Oncology 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Small Molecule to Inhibit Galectin-3 for Fibrosis, Cancer and Cardiovascular Disease 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Small Molecules to Antagonize E-Selectin for Cardiovascular Disease, Cancer and Inflammation 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
GlycoMimetics, Inc. - Pipeline Analysis 21
GlycoMimetics, Inc. - Pipeline Products by Target 21
GlycoMimetics, Inc. - Pipeline Products by Route of Administration 22
GlycoMimetics, Inc. - Pipeline Products by Molecule Type 23
GlycoMimetics, Inc. - Pipeline Products by Mechanism of Action 24
GlycoMimetics, Inc. - Recent Pipeline Updates 25
GlycoMimetics, Inc. - Dormant Projects 28
GlycoMimetics, Inc. - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31

List of Tables
GlycoMimetics, Inc., Key Information 5
GlycoMimetics, Inc., Key Facts 5
GlycoMimetics, Inc. - Pipeline by Indication, 2015 7
GlycoMimetics, Inc. - Pipeline by Stage of Development, 2015 8
GlycoMimetics, Inc. - Monotherapy Products in Pipeline, 2015 9
GlycoMimetics, Inc. - Out-Licensed Products in Pipeline, 2015 10
GlycoMimetics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
GlycoMimetics, Inc. - Phase I, 2015 12
GlycoMimetics, Inc. - Preclinical, 2015 13
GlycoMimetics, Inc. - Pipeline by Target, 2015 21
GlycoMimetics, Inc. - Pipeline by Route of Administration, 2015 22
GlycoMimetics, Inc. - Pipeline by Molecule Type, 2015 23
GlycoMimetics, Inc. - Pipeline Products by Mechanism of Action, 2015 24
GlycoMimetics, Inc. - Recent Pipeline Updates, 2015 25
GlycoMimetics, Inc. - Dormant Developmental Projects,2015 28

List of Figures
GlycoMimetics, Inc. - Pipeline by Top 10 Indication, 2015 7
GlycoMimetics, Inc. - Pipeline by Stage of Development, 2015 8
GlycoMimetics, Inc. - Monotherapy Products in Pipeline, 2015 9
GlycoMimetics, Inc. - Pipeline by Top 10 Target, 2015 21
GlycoMimetics, Inc. - Pipeline by Top 10 Route of Administration, 2015 22
GlycoMimetics, Inc. - Pipeline by Top 10 Molecule Type, 2015 23
GlycoMimetics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.